| Literature DB >> 26228239 |
Kazuyoshi Kato1,2, Kyoko Nishikimi3, Shinichi Tate4, Takako Kiyokawa5, Makio Shozu6.
Abstract
BACKGROUND: To achieve optimal cytoreduction for advanced-stage ovarian cancer, modified posterior exenteration is the most frequently performed bowel surgery. We assessed the extents of tumor spreading in the rectosigmoid wall and pelvic side wall in modified posterior exenteration specimens during primary debulking surgery (PDS) and interval debulking surgery (IDS) following neoadjuvant chemotherapy, and compared the validity of selecting this surgical procedure in the patients undergoing PDS with that in the patients undergoing IDS.Entities:
Mesh:
Year: 2015 PMID: 26228239 PMCID: PMC4521360 DOI: 10.1186/s12957-015-0647-x
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Surgical specimen of a posterior exenteration with the left pelvic side wall resection. a Ventral view of an en bloc resection specimen of the pelvic side wall tissue together with the uterus, adnexa, rectosigmoid, and ileum. The specimen included intact parietal pelvis tissue around the tumor spreading in the deep retroperitoneal space (arrowheads). b Cut surface of the specimen. Tumor infiltration into the mucosa of the rectal wall can be seen (white arrows). The framed rectangle corresponds to the area shown in Fig. 1c. c Histopathologic section of the specimen showed tumor infiltration into the skeletal muscle (hematoxylin and eosin staining, ×20)
Patient and tumor characteristics
| Characteristics | Result |
|---|---|
| Age, median (range), y | 60 (31–83) |
| Diagnosis and stage | |
| Ovarian cancer ( | |
| IC | 5 |
| IIC | 6 |
| IIIB | 1 |
| IIIC | 26 |
| IV | 15 |
| Tubal cancer ( | |
| IIC | 1 |
| IIIB | 2 |
| IIIC | 12 |
| IV | 2 |
| Peritoneal cancer ( | |
| IIIC | 4 |
| IV | 1 |
| Histology, n (%) | |
| Serous | 48 (64) |
| Clear cell | 8 (11) |
| Endometrioid | 7 (9) |
| Others | 12 (16) |
| Largest size of pelvic tumor at surgery, | |
| <50 mm | 22 (29) |
| 50–100 mm | 18 (24) |
| >100 mm | 35 (47) |
| Pelvic lymph node involvement, | |
| Positive | 26 (35) |
| Negative | 38 (51) |
| No pelvic lymph nodes found | 11 (15) |
Differences in the extent of tumor spreading in the rectosigmoid wall between patients who underwent a modified posterior exenteration in the PDS group and those in the IDS group
| Characteristics | PDS ( | IDS ( |
|
|---|---|---|---|
| Rectosigmoid wall involvement | 0.939 | ||
| Positive | 25 | 24 | |
| Depth of tumor invasion | 0.012 | ||
| Mucosal or submucosal layer | 7 | 3 | |
| Muscular layer | 11 | 5 | |
| Serosal layer | 7 | 16 | |
| Negative | 13 | 13 | |
| Factor in rectosigmoid adhesion | 0.706 | ||
| Tumor involvement of the mesocolon | 2 | 1 | |
| Tumor involvement of the peritoneum of the cul-de-sac | 4 | 2 | |
| Fibrosis, necrosis, and/or granulation | 3 | 8 | |
| Endometriosis | 3 | 1 | |
| No histopathologic finding | 1 | 1 |
PDS primary debulking surgery, IDS interval debulking surgery after neoadjuvant chemotherapy
Differences in the extent of tumor spreading in the pelvic side wall between patients who underwent a modified posterior exenteration with pelvic side wall resection in the PDS group and those in the IDS group
| Characteristics | PDS ( | IDS ( |
|
|---|---|---|---|
| Pelvic side wall involvement | 0.354 | ||
| Positive | 8 | 2 | |
| Extent of tumor spread | 0.435 | ||
| Parametrium and/or paracolpium | 8 | 2 | |
| Cardinal ligament and/or deep retroperitoneal space | 3 | 1 | |
| Ureter | 1 | 0 | |
| Internal iliac vessels | 0 | 0 | |
| Levator ani muscle | 1 | 0 | |
| Negative | 4 | 3 | |
| Pelvic lymph node involvement | 1.000 | ||
| Positive | 5 | 2 | |
| Negative | 7 | 3 |